Zileuton
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Zileuton
|
|
| Systematic (IUPAC) name | |
| 1-(1-benzothiophen-2-ylethyl)-1-hydroxy-urea | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C11H12N2O2S |
| Mol. mass | 236.291 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Not yet established |
| Protein binding | 93% |
| Metabolism | Hepatic (CYP1A2, CYP2C9 and CYP3A4-mediated) |
| Half life | 2.5 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status | |
| Routes | Oral |
Zileuton (INN) is an asthma drug. It blocks leukotriene synthesis by inhibiting 5-lipoxygenase, an enzyme of the eicosanoid synthesis pathway.
Zileuton is marketed by Critical Therapeutics under the brand name Zyflo®.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
